We help you join the dots...

RAS LSS is a niche strategy consultancy serving the global life sciences sector

 
 

Starting with Information Services in 2014, RAS LSS has evolved into a boutique healthcare consulting group. We offer a niche portfolio of Strategy Support and Information Services to Pharmaceutical and Medical Device Companies, throughout the product life-cycle.

We elucidate and contextualize current and future market complexities. Leveraging our collective intelligence, we strive to help our clients succeed via

  • Best In Class Situation Analysis
  • Competitively Differentiated Strategy
With an outreach across mature and emerging markets, we go the extra mile to create fresh perspectives for our clients in their mission to reduce the global burden of disease.


We have put in the hours and the sweat to be credible…


Latest Blogs

August 8, 2019
antibiotics

Innovations in Antibiotics – Hope or Too Little Too Late?

A brief history Even though Alexander Fleming discovered the first antibiotic penicillin in 1928, it was introduced into the market as a commercial therapeutic for bacterial infection, only in 1940. It was Gerhard Domaghk who developed the first commercial antibacterial Prontosil, a sulfonamide, in 1930s. The introduction of penicillin marked […]
August 2, 2019
Phenotype

Classical Pharmacology is Dead: Long Live Phenotypic Screening!

  The tediously long and risk-laden process of translating a discovery in biology to a marketable medical breakthrough starts with identifying a repertoire of molecules that will bring about the desired effect. What is it, really? Let´s start with the basics – the definition of phenotype itself. A phenotype is […]
July 29, 2019
drug_delivery

Innovations in Drug Delivery System – Injectables

Since 2015, the global injectable/parenteral drug delivery market is growing at a compounded rate of 11.8% and is forecasted to reach $640 million by 2021. It has the potential to soon eclipse oral delivery as the primary route of administration of pharmaceuticals, driven by the increased use of biological drugs.1 […]
July 24, 2019
VBC

Value-Based Contracts in Pharma – A buzz or a game changer?

The healthcare industry has been talking about adopting a ‘value-based care’ for some time now.1 Overall, the healthcare systems globally are going through a ‘volume-to-value’ shift with the key aim to improve patient outcomes, cost-effectively. Value-Based Contracting (VBC) and Real-World Evidence (RWE) are the underlying tools to achieve value-based care. […]
July 23, 2019
RNA

Biology’s Central Dogma Has Been Overturned! So What?

In August 2018, patisiran, a first-in-class therapy was approved in the US and EU to treat the polyneuropathy associated with a genetic disease 002D hereditary transthyretin-mediated amyloidosis. The therapy uses small pieces of ribonucleic acid (RNA) to effectively ‘silence’ a faulty gene, without changing the deoxy ribonucleic acid (DNA) of […]
July 19, 2019
Repurposing

Old wine in a new bottle? Introduction to Drug Repurposing

Translating a discovery in biology to a marketable medical breakthrough is a long drawn, tedious, high-investment, and high-risk process. Drug repurposing / repositioning has turned into a popular strategy of late. Not quite the same as traditional drug development techniques, the strategy is productive, affordable and is associated with reduced […]